{"id":"belsomra","rwe":[],"tags":[],"phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Somnolence","drugRate":"8.5%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":837,"totalAffected":71,"trialsReporting":4},{"effect":"Headache","drugRate":"7.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":856,"totalAffected":60,"trialsReporting":6},{"effect":"Fatigue","drugRate":"7.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":604,"totalAffected":45,"trialsReporting":3},{"effect":"Nasopharyngitis","drugRate":"8.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":521,"totalAffected":42,"trialsReporting":1},{"effect":"headache","drugRate":"7.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":520,"totalAffected":37,"trialsReporting":3},{"effect":"somnolence","drugRate":"7.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":520,"totalAffected":37,"trialsReporting":3},{"effect":"Upper respiratory tract infection","drugRate":"5.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":521,"totalAffected":28,"trialsReporting":1},{"effect":"Dizziness","drugRate":"4.7%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":533,"totalAffected":25,"trialsReporting":2},{"effect":"Constipation","drugRate":"21.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":113,"totalAffected":24,"trialsReporting":2},{"effect":"Insomnia","drugRate":"16.8%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":113,"totalAffected":19,"trialsReporting":2},{"effect":"nasopharnygitis","drugRate":"7.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":254,"totalAffected":18,"trialsReporting":1},{"effect":"Delirium","drugRate":"17.8%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":101,"totalAffected":18,"trialsReporting":1},{"effect":"Vomiting","drugRate":"12.9%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":101,"totalAffected":13,"trialsReporting":1},{"effect":"Nausea","drugRate":"7.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":113,"totalAffected":8,"trialsReporting":2},{"effect":"Observed somnolence","drugRate":"12.1%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":66,"totalAffected":8,"trialsReporting":1},{"effect":"Fall","drugRate":"6.9%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":101,"totalAffected":7,"trialsReporting":1},{"effect":"Procedural pain","drugRate":"5.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":101,"totalAffected":5,"trialsReporting":1},{"effect":"Wound complication","drugRate":"5.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":101,"totalAffected":5,"trialsReporting":1},{"effect":"Grogginess","drugRate":"22.7%","organSystem":"General disorders","placeboRate":"","totalAtRisk":22,"totalAffected":5,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"4.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":101,"totalAffected":4,"trialsReporting":1},{"effect":"Dream Abnormal","drugRate":"33.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":12,"totalAffected":4,"trialsReporting":1},{"effect":"Abnormal Dreams","drugRate":"4.5%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":66,"totalAffected":3,"trialsReporting":1},{"effect":"Vivid dreams","drugRate":"13.6%","organSystem":"General disorders","placeboRate":"","totalAtRisk":22,"totalAffected":3,"trialsReporting":1},{"effect":"Abdominal Distention","drugRate":"25.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":12,"totalAffected":3,"trialsReporting":1},{"effect":"dry mouth","drugRate":"11.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":27,"totalAffected":3,"trialsReporting":1},{"effect":"Vivid Dreams","drugRate":"8.8%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":34,"totalAffected":3,"trialsReporting":1},{"effect":"Worsened RLS","drugRate":"8.8%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":34,"totalAffected":3,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.8%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":249,"totalAffected":2,"trialsReporting":1},{"effect":"Self-reported somnolence","drugRate":"3.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":66,"totalAffected":2,"trialsReporting":1},{"effect":"Hypnagogic Hallucinations","drugRate":"3.0%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":66,"totalAffected":2,"trialsReporting":1},{"effect":"Abnormal thought/hallucination","drugRate":"4.1%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":49,"totalAffected":2,"trialsReporting":1},{"effect":"Sleep Disturbances","drugRate":"11.1%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":18,"totalAffected":2,"trialsReporting":1},{"effect":"gastro-intestinal symptoms","drugRate":"7.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":27,"totalAffected":2,"trialsReporting":1},{"effect":"mood symptoms","drugRate":"7.4%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":27,"totalAffected":2,"trialsReporting":1},{"effect":"Mood Alteration (Depression/Anxiety/Irritability)","drugRate":"5.9%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":34,"totalAffected":2,"trialsReporting":1},{"effect":"Worsened Insomnia","drugRate":"5.9%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":34,"totalAffected":2,"trialsReporting":1},{"effect":"Dry Mouth","drugRate":"2.5%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":40,"totalAffected":1,"trialsReporting":2},{"effect":"Abdominal Cramp","drugRate":"8.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Indigestion","drugRate":"8.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Agitation","drugRate":"8.3%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Anxiety","drugRate":"8.3%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Drowsiness","drugRate":"8.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Euphoria","drugRate":"8.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Impaired/Groggy","drugRate":"8.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Irritability","drugRate":"8.3%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Light headed","drugRate":"8.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Photophobia","drugRate":"8.3%","organSystem":"Eye disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Pruritus","drugRate":"8.3%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Sweat Increased","drugRate":"8.3%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1},{"effect":"Blurred Vision","drugRate":"8.3%","organSystem":"Eye disorders","placeboRate":"","totalAtRisk":12,"totalAffected":1,"trialsReporting":1}],"contraindications":["Narcolepsy"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"event":"Neuropathy","detail":"Surgical and medical procedures. 1 trial(s).","severity":"serious","incidence":"4.5%"},{"event":"Paroxysmal Atrial Tachycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Postoperative Spinal Abscess","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Wound dehiscence","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Wound Infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Abdominal Fluid Collection","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Increased Postoperative Pain","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Surgical Incision Swelling","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Hypoglycemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Death due to persistent comatose state","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Intraparenchymal hemorrhage","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Acute Kidney Injury","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Pulmonary embolism","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"1.5%"},{"event":"Pyelonephritis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Urosepsis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Periprosthetic fracture","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Post procedural haemorrhage","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Bladder cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Urinary bladder haemorrhage","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Ankle fracture","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.7%"},{"event":"pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"ankle fracture","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Diverticulitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Basal cell carcinoma","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Pneumonia","detail":"Infections and infestations. 2 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"atrial fibrillation","detail":"Cardiac disorders. 2 trial(s).","severity":"serious","incidence":"0.2%"},{"event":"Atrial fibrillation","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.2%"},{"event":"Coronary artery disease","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.2%"},{"event":"Vertigo positional","detail":"Ear and labyrinth disorders. 1 trial(s).","severity":"serious","incidence":"0.2%"},{"event":"Gastrooesophageal reflux","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.2%"}]},"status":"active","trials":["NCT04629547","NCT04706091","NCT07214207","NCT03937986","NCT02593682","NCT04092894","NCT06326684","NCT05733286","NCT05145764","NCT06655883","NCT03657355","NCT02785406","NCT02729714","NCT06484075","NCT05546554","NCT06679062","NCT05711862","NCT06854224","NCT04287062","NCT02849548","NCT04229095","NCT04571944","NCT02750306","NCT01059851","NCT03764683","NCT03999099","NCT02527564","NCT02704754","NCT03789214","NCT05593653","NCT05908526","NCT06788522","NCT01097616","NCT01097629","NCT01311882","NCT03818581","NCT03312517","NCT06584942","NCT03158025","NCT03034018","NCT02669030","NCT04273776","NCT03077620","NCT03642028","NCT05106153","NCT04014387","NCT03897062","NCT02491788","NCT01293006","NCT06162663"],"aliases":[],"patents":[],"pricing":[],"_sources":{"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (14 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T10:26:33.565176+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Belsomra","companyId":"national-institute-on-drug-abuse-nida","ecosystem":[],"mechanism":{"target":"Orexin receptor type 1, Orexin receptor type 2, Orexin receptor type 1","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T10:26:40.799655+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"companyName":"National Institute on Drug Abuse (NIDA)","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Belsomra","indications":{"approved":[{"name":"Insomnia","diseaseId":"insomnia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04629547","phase":"Phase 2","title":"Sleep Trial to Prevent Alzheimer's Disease","status":"RECRUITING","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":200,"indication":"Sleep, Alzheimer Disease","completionDate":"2026-05"},{"nctId":"NCT04706091","phase":"Phase 4","title":"Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia: A Randomized Placebo-Controlled Crossover Trial","status":"COMPLETED","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":46,"indication":"Restless Legs Syndrome, Insomnia","completionDate":"2023-10-20"},{"nctId":"NCT07214207","phase":"Phase 2","title":"Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking","status":"RECRUITING","sponsor":"Ohio State University","isPivotal":false,"enrollment":250,"indication":"Alcohol Use Disorder","completionDate":"2030-09"},{"nctId":"NCT03937986","phase":"EARLY/Phase 1","title":"Influence of Orexin Antagonism on Motivation for Cocaine","status":"COMPLETED","sponsor":"William Stoops","isPivotal":false,"enrollment":8,"indication":"Cocaine Use Disorder","completionDate":"2022-04-30"},{"nctId":"NCT02593682","phase":"Phase 4","title":"The Role of Orexin in Human Panic Disorder","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":3,"indication":"Panic Disorder","completionDate":"2020-03-13"},{"nctId":"NCT04092894","phase":"Phase 4","title":"Effects of the Orexin Receptor Antagonist Suvorexant on Sleep Architecture and Delirium in the Intensive Care Unit: A Multi-Centric Randomized Controlled Trial","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","isPivotal":false,"enrollment":100,"indication":"Insomnia, Sleep Fragmentation","completionDate":"2025-07-01"},{"nctId":"NCT06326684","phase":"EARLY/Phase 1","title":"Influence of Orexin Antagonism on Motivation for Alcohol","status":"RECRUITING","sponsor":"William Stoops","isPivotal":false,"enrollment":30,"indication":"Alcohol Use Disorder","completionDate":"2027-03-15"},{"nctId":"NCT05733286","phase":"Phase 2","title":"Efficacy of Suvorexant to Improve Postoperative Sleep and Reduce Delirium Severity in Older Surgical Patients: A Double-blinded, Randomized, Placebo-controlled Trial","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":142,"indication":"Delirium in Old Age","completionDate":"2025-07-07"},{"nctId":"NCT05145764","phase":"Phase 2","title":"Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl","status":"RECRUITING","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":120,"indication":"Suvorexant, Placebo","completionDate":"2026-08"},{"nctId":"NCT06655883","phase":"Phase 3","title":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":300,"indication":"Insomnia","completionDate":"2027-06-24"},{"nctId":"NCT03657355","phase":"Phase 1","title":"Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","isPivotal":false,"enrollment":63,"indication":"Healthy Recreational Drug Users","completionDate":"2019-08-08"},{"nctId":"NCT02785406","phase":"Phase 2","title":"Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","isPivotal":false,"enrollment":20,"indication":"Cocaine Use Disorder, Anxiety","completionDate":"2018-11-15"},{"nctId":"NCT02729714","phase":"Phase 4","title":"A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease","status":"COMPLETED","sponsor":"Burdick, Daniel, M.D.","isPivotal":false,"enrollment":21,"indication":"Insomnia","completionDate":"2022-04"},{"nctId":"NCT06484075","phase":"Phase 1","title":"Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","isPivotal":false,"enrollment":180,"indication":"Healthy Volunteers, Alcohol Use Disorder (AUD)","completionDate":"2029-12-31"},{"nctId":"NCT05546554","phase":"Phase 2","title":"Randomized Placebo-Controlled Crossover Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","isPivotal":false,"enrollment":26,"indication":"Autism, Autism Spectrum Disorder","completionDate":"2028-02-28"},{"nctId":"NCT06679062","phase":"Phase 2","title":"A Double-masked, Randomized, Phase II Study to Compare the Effectiveness of 20mg Oral Suvorexant (SUV) Versus Placebo (1:1) in Participants With Co-occurring Alcohol Use Disorder (AUD) and Posttraumat","status":"RECRUITING","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","isPivotal":false,"enrollment":76,"indication":"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)","completionDate":"2026-06"},{"nctId":"NCT05711862","phase":"Phase 2","title":"The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","isPivotal":false,"enrollment":7,"indication":"Methamphetamine Use Disorder","completionDate":"2024-03-28"},{"nctId":"NCT06854224","phase":"Phase 2","title":"Orexin Antagonism to Target Mechanisms of Suicide Risk: A Proof-of-Concept Clinical Trial","status":"RECRUITING","sponsor":"Marianne Goodman","isPivotal":false,"enrollment":30,"indication":"Suicide Risk, Major Depressive Disorder (MDD)","completionDate":"2027-07-01"},{"nctId":"NCT04287062","phase":"Phase 2","title":"Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder","status":"COMPLETED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":138,"indication":"Sleep Disturbance, Opioid-use Disorder","completionDate":"2025-08-15"},{"nctId":"NCT02849548","phase":"Phase 4","title":"Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?","status":"COMPLETED","sponsor":"Howard University","isPivotal":false,"enrollment":27,"indication":"Posttraumatic Stress Disorder","completionDate":"2021-05-19"},{"nctId":"NCT04229095","phase":"Phase 2","title":"Medication Development for Protracted Abstinence in Alcoholism: Suvorexant Versus Placebo","status":"COMPLETED","sponsor":"The Scripps Research Institute","isPivotal":false,"enrollment":26,"indication":"Alcohol Use Disorder (AUD)","completionDate":"2022-11-08"},{"nctId":"NCT04571944","phase":"Phase 3","title":"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of MK-4305 (Suvorexant) for Reducing Incidence of Delirium in Japanese Participan","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":207,"indication":"Delirium","completionDate":"2022-12-23"},{"nctId":"NCT02750306","phase":"Phase 3","title":"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":285,"indication":"Sleep Initiation and Maintenance Disorders, Alzheimer Disease","completionDate":"2018-09-30"},{"nctId":"NCT01059851","phase":"Phase 1","title":"An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4305 in Patients With Impaired Renal Function","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":16,"indication":"Insomnia","completionDate":"2010-07-15"},{"nctId":"NCT03764683","phase":"Phase 4","title":"A Double-Blind Sequential Parallel Study of Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":0,"indication":"Bipolar Disorder, Insomnia","completionDate":"2021-01-06"},{"nctId":"NCT03999099","phase":"Phase 1","title":"Targeting Orexin to Treat Nicotine Dependence","status":"UNKNOWN","sponsor":"Mclean Hospital","isPivotal":false,"enrollment":45,"indication":"Nicotine Dependence","completionDate":"2024-12-01"},{"nctId":"NCT02527564","phase":"Phase 4","title":"A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Suvorexant for Treatment-resistant Insomnia in Patients With Bipolar Disorder","status":"COMPLETED","sponsor":"Stanford University","isPivotal":false,"enrollment":61,"indication":"Insomnia, Bipolar Disorder","completionDate":"2021-03-01"},{"nctId":"NCT02704754","phase":"Phase 4","title":"Suvorexant and Trauma Related Insomnia","status":"COMPLETED","sponsor":"Howard University","isPivotal":false,"enrollment":41,"indication":"Insomnia, Posttraumatic Stress Disorder","completionDate":"2021-04-30"},{"nctId":"NCT03789214","phase":"Phase 2","title":"Medical Management of Sleep Disturbance During Opioid Tapering","status":"COMPLETED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":90,"indication":"Opioid Dependence, Opioid Withdrawal","completionDate":"2021-06-10"},{"nctId":"NCT05593653","phase":"Phase 4","title":"Treating Insomnia and Improving Glycemic Control in Midlife Women With Insomnia and Pre-diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","isPivotal":false,"enrollment":61,"indication":"Insomnia, Diabetes","completionDate":"2025-12-31"},{"nctId":"NCT05908526","phase":"Phase 2","title":"The Impact of Suvorexant on Cognitive Function and Daytime Symptoms Among Community-dwelling Older Adults With Insomnia: A Placebo-controlled, Randomized Clinical Trial Using Remote Monitoring and Eco","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","isPivotal":false,"enrollment":40,"indication":"Insomnia","completionDate":"2024-08-08"},{"nctId":"NCT06788522","phase":"Phase 4","title":"The Effects of Orexin Antagonism on Fear Extinction in PTSD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":40120,"indication":"Insomnia, PTSD","completionDate":"2032-06-30"},{"nctId":"NCT01097616","phase":"Phase 3","title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study A","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":1023,"indication":"Primary Insomnia","completionDate":"2011-12-07"},{"nctId":"NCT01097629","phase":"Phase 3","title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study B","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":1020,"indication":"Primary Insomnia","completionDate":"2011-11-08"},{"nctId":"NCT01311882","phase":"Phase 1","title":"A Multiple Dose Study to Evaluate Next Day Effects of MK-4305 on Driving Performance in Healthy Non-Elderly Subjects","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":28,"indication":"Insomnia","completionDate":"2011-11"},{"nctId":"NCT03818581","phase":"Phase 4","title":"Effect of Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes: A Randomized 3-month Clinical Trial Using a Sequential Parallel Comparison Desi","status":"COMPLETED","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":108,"indication":"Type 2 Diabetes Mellitus, Insomnia","completionDate":"2021-11-03"},{"nctId":"NCT03312517","phase":"Phase 4","title":"A Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (Responsivity) of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs","status":"COMPLETED","sponsor":"Henry Ford Health System","isPivotal":false,"enrollment":12,"indication":"Insomnia","completionDate":"2018-10-25"},{"nctId":"NCT06584942","phase":"Phase 4","title":"Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder","status":"RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":20,"indication":"Cue-reactivity, Cannabis Use Disorder","completionDate":"2026-07"},{"nctId":"NCT03158025","phase":"Phase 1","title":"A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreatio","status":"COMPLETED","sponsor":"Eisai Inc.","isPivotal":false,"enrollment":39,"indication":"Insomnia Disorders","completionDate":"2018-07-04"},{"nctId":"NCT03034018","phase":"Phase 4","title":"A Double-blind, Randomized, Placebo-controlled Study to Determine the Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia in Midlife Women","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","isPivotal":false,"enrollment":60,"indication":"Insomnia","completionDate":"2020-04-03"},{"nctId":"NCT02669030","phase":"Phase 4","title":"A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia","status":"UNKNOWN","sponsor":"Institute for Advanced Medical Research, Alpharetta, GA","isPivotal":false,"enrollment":74,"indication":"Depression, Major Depressive Disorder","completionDate":"2019-12"},{"nctId":"NCT04273776","phase":"EARLY/Phase 1","title":"A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walter Reed Army Institute of Research (WRAIR)","isPivotal":false,"enrollment":90,"indication":"Performance Enhancing Product Use","completionDate":"2025-12-12"},{"nctId":"NCT03077620","phase":"NA","title":"Sleep Quality and Amyloid-Beta Kinetics","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":48,"indication":"Amyloid-beta","completionDate":"2021-03-30"},{"nctId":"NCT03642028","phase":"Phase 4","title":"Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance inPosttraumatic Stress","status":"RECRUITING","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":190,"indication":"Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic","completionDate":"2025-12-31"},{"nctId":"NCT05106153","phase":"Phase 1","title":"A Single-Dose, Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Determine the Abuse Potential of Single Oral Dose of Seltorexant Compared To Suvorexant and Zolpidem","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":127,"indication":"Healthy Non-dependent, Recreational Sedative Users, Abuse Potential","completionDate":"2023-05-12"},{"nctId":"NCT04014387","phase":"Phase 4","title":"Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":40,"indication":"Treatment","completionDate":"2025-06-30"},{"nctId":"NCT03897062","phase":"Phase 2","title":"A Placebo-controlled, Double -Blind Randomised Trial of Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence","status":"TERMINATED","sponsor":"The Florey Institute of Neuroscience and Mental Health","isPivotal":false,"enrollment":22,"indication":"Insomnia, Alcohol Use Disorder","completionDate":"2022-07-31"},{"nctId":"NCT02491788","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"VA Palo Alto Health Care System","isPivotal":false,"enrollment":19,"indication":"Sleep Disorder, Shift-Work","completionDate":"2019-08-01"},{"nctId":"NCT01293006","phase":"Phase 1","title":"A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":25,"indication":"Insomnia","completionDate":"2012-02-22"},{"nctId":"NCT06162663","phase":"Phase 4","title":"Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors","status":"TERMINATED","sponsor":"Medical University of South Carolina","isPivotal":false,"enrollment":5,"indication":"Breast Cancer, Insomnia","completionDate":"2026-02-17"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"structuredTrialResults":[{"hr":"19.6","nctId":"NCT01097616","phase":"PHASE3","pValue":"<0.00001","ciLower":"12.0","ciUpper":"27.1","endpoint":"Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1","enrollment":1023},{"hr":"26.3","nctId":"NCT01097629","phase":"PHASE3","pValue":"<0.00001","ciLower":"18.3","ciUpper":"34.3","endpoint":"Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1","enrollment":1020},{"hr":"0.4","nctId":"NCT01021813","phase":"PHASE3","pValue":"","ciLower":"-1.1","ciUpper":"1.4","endpoint":"Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment Phase","enrollment":781},{"hr":"28.2","nctId":"NCT02750306","phase":"PHASE3","pValue":"0.00128","ciLower":"11.1","ciUpper":"45.2","endpoint":"Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4","enrollment":285},{"hr":"12.9","nctId":"NCT00792298","phase":"PHASE2","pValue":"<0.001","ciLower":"9.5","ciUpper":"16.3","endpoint":"LS Mean Sleep Efficiency (SE) During Periods 1 and 2","enrollment":254},{"hr":"-8.7","nctId":"NCT04571944","phase":"PHASE3","pValue":"0.129","ciLower":"-20.1","ciUpper":"2.6","endpoint":"Percentage of Participants With Delirium as Assessed by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria","enrollment":207},{"hr":"","nctId":"NCT05733286","phase":"PHASE2","pValue":"0.853","ciLower":"","ciUpper":"","endpoint":"Total Sleep Time (TST) on the First Postoperative Night","enrollment":142},{"hr":"","nctId":"NCT03818581","phase":"PHASE4","pValue":"0.15","ciLower":"","ciUpper":"","endpoint":"Subjective Total Sleep Time","enrollment":108},{"hr":"","nctId":"NCT03789214","phase":"PHASE2","pValue":".950","ciLower":"","ciUpper":"","endpoint":"Abuse Liability as Assessed by Visual Analogue Scale","enrollment":90},{"hr":"0.41","nctId":"NCT05656534","phase":"EARLY_PHASE1","pValue":".19","ciLower":"-0.20","ciUpper":"1.10","endpoint":"Startle Eyeblink Electromyographic (EMG) Response to Stress With an Acute Dose of Suvorexant","enrollment":81},{"hr":"","nctId":"NCT02704754","phase":"PHASE4","pValue":"<.05","ciLower":"","ciUpper":"","endpoint":"Change in Insomnia Severity Index Score From Baseline.","enrollment":41}],"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":18,"withResults":14},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T10:26:40.799655+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}